Media
Check out our latest corporate updates, features in the media, and scientific publications and presentations.
Press Releases
Media
- Candel’s CEO looks to help ignite a new era of cancer treatments
- After flicker, investor enthusiasm for Candel burns brighter
- Newly public Candel looks to two years of value inflection points
- Candel Therapeutics, Inc NASDAQ Bell Ringing
- After building pipelines from GlaxoSmithKline to Flagship, Paul Peter Tak takes the helm at an under-the-radar oncolytic virus player
- Tak lands at Candel, with plans to speed up development of immunotherapy’s play late-stage assets
- Ex-GSK immunology chief takes over oncolytic virus biotech Candel as it ramps up its pipeline
Presentations & Publications
- Patrick Y. Wen, MD, 26th Annual Meeting of the Society for Neuro-Oncology (SNO), Phase 1 clinical trial of oncolytic viral immunotherapy with CAN-2409 + valacyclovir in combination with nivolumab and standard of care in newly diagnosed high-grade glioma
- Candel Poster, The Society for Immunotherapy of Cancer’s 36th Annual Meeting, Detection of viral antigen and immune activation after intra-tumor injection of CAN-3110 (ICP-34.5 expressing HSV-1 oncolytic virus) in patients with recurrent high-grade glioma [Link will download as a .pptx file]
- Candel Poster, The 28th Annual Prostate Cancer Foundation’s Scientific Retreat, Patient experience with intraprostatic injection of CAN-2409 or placebo followed by valacyclovir in a phase 3 clinical trial for localized prostate cancer in combination with standard of care radiation therapy with or without androgen suppression
- Rahman et al, The Lancet Oncology 2021
Leveraging external data in the design and analysis of clinical trials in neuro-oncology - Paul Peter Tak, MD, PhD, FMedSci, Cambridge Healthtech Institute’s 9th Annual Immuno-Oncology Summit: Oncolytic Virus Immunotherapy, Tipping the balance in favor of the immune system to fight cancer
- Scott Eggener, MD Fifth Global Summit on Precision Diagnosis and Treatment of Prostate Cancer
Safety and Feasibility of Intraprostatic Injection of CAN-2409 or Placebo followed by Valacyclovir in Patients on Active Surveillance for Prostate Cancer (ULYSSES Trial) - E. Antonio Chiocca, MD PhD, 2021 ASCO Annual Meeting
First in human clinical trial with CAN-3110 (ICP-34.5 expressing HSV-1 oncolytic virus) in patients with recurrent high-grade glioma - Predina et al, Molecular Therapy 2020
Neoadjuvant Gene-Mediated Cytotoxic Immunotherapy for Non-Small-Cell Lung Cancer: Safety and Immunologic Activity - Kieran et al, Neuro-Oncology 2019
Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma - Aggarwal et al, Molecular Therapy 2018
Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural Effusion - Speranza et al, Neuro-Oncology 2018
Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma - Wheeler et al, Neuro-Oncology 2016
Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma - Aguilar et al, Cancer Immunology, Immunotherapy 2015
Gene‑mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma
Candel Therapeutics Announces Pricing of Initial Public Offering
Press ReleaseCandel Therapeutics Appoints Diem Nguyen, Ph.D., M.B.A., to its Board of Directors
Press ReleaseCandel Therapeutics Announces Data from Phase 1 Trial of CAN-3110 in Recurrent High-Grade Glioma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
Press ReleaseCandel Therapeutics to Present at Upcoming Jefferies Virtual Healthcare Conference
Press ReleaseCandel Therapeutics Names Carrie S. Cox as Chairman of its Board of Directors
Press ReleaseCandel Therapeutics’ CAN-3110 Clinical Data Selected for Oral Presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
Press ReleaseCandel Therapeutics Completes Enrollment in Phase 1 Clinical Trial of CAN-2409 in Combination with Opdivo® (nivolumab) for the Treatment of High-Grade Gliomas
Press ReleaseCandel Therapeutics Announces Formation of New Research Advisory Board Comprised of Multiple Prominent Scientists and Clinicians including 2018 Nobel Laureate, James Allison, Ph.D.
Press ReleaseCandel Therapeutics Appoints Chris Matheny, PharmD, Ph.D., as Vice President, Development Leader
Press ReleaseCandel Therapeutics Appoints Pharma Veteran and Immunologist Paul-Peter Tak, M.D., Ph.D., as Chief Executive Officer; Expands Leadership Team With Chief Financial Officer, Chief Business Officer and Chief Regulatory Officer Appointments
Press ReleaseCandel Therapeutics Announces Presentation of Clinical Data for GMCI in NSCLC at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting
Press ReleaseCandel Therapeutics Announces Presentation at the 2020 American Society of Gene and Cell Therapy (ASGCT) 23rd Annual Meeting
Press ReleaseCandel Therapeutics acquires next-generation herpes drug development platform and manufacturing expertise
Press Release